摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-Morpholin-4-yl-piperidin-1-yl)-ethanone | 96921-42-5

中文名称
——
中文别名
——
英文名称
1-(4-Morpholin-4-yl-piperidin-1-yl)-ethanone
英文别名
1-[4-(Morpholin-4-yl)piperidin-1-yl]ethan-1-one;1-(4-morpholin-4-ylpiperidin-1-yl)ethanone
1-(4-Morpholin-4-yl-piperidin-1-yl)-ethanone化学式
CAS
96921-42-5
化学式
C11H20N2O2
mdl
——
分子量
212.292
InChiKey
YJTXKEGWGBVPGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    1-(4-吗啉-4-基-3,6-二氢-2H-吡啶-1-基)乙酮甲酸 作用下, 反应 2.0h, 以54%的产率得到1-(4-Morpholin-4-yl-piperidin-1-yl)-ethanone
    参考文献:
    名称:
    Nilsson, Asa; Carlson, Rolf, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1985, vol. 39, # 3, p. 187 - 190
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
    申请人:SHY Therapeutics LLC
    公开号:US20170174699A1
    公开(公告)日:2017-06-22
    Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    本文提供了抑制MAPK磷酸化的化合物,因此可用于治疗癌症和炎症性疾病的组合物和方法。
  • [EN] NOVEL CHOLINE KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE CHOLINE KINASE
    申请人:ARIAD PHARMA INC
    公开号:WO2014151761A1
    公开(公告)日:2014-09-25
    This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
    这项发明涉及通式(I)的化合物,其中变量基团如本说明中所识别的,并涉及该化合物的制备和使用。
  • Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
    申请人:Iida Kyoichiro
    公开号:US20070213361A1
    公开(公告)日:2007-09-13
    The present invention provides a preventive and/or therapeutic agent for neutrophilic inflammatory diseases which comprises as an active ingredient, a bicyclic heterocyclic compound represented by formula (I): [wherein R 1 represents a hydrogen atom, substituted or unsubstituted alkyl, or the like, A 1 -A 2 -A 3 -A 4 represents N═CR 3 —CR 4 ═CR 5 (wherein R 3 , R 4 , and R 5 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like), Q represents substituted or unsubstituted phenylene, and the like, and T represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aroyl, and the like].
    本发明提供了一种用于中性粒细胞炎症性疾病的预防和/或治疗剂,其包括以下式(I)所表示的双环杂环化合物作为活性成分:[其中,R1代表氢原子,取代或未取代的烷基等;A1-A2-A3-A4代表N═CR3—CR4═CR5(其中,R3、R4和R5相同或不同,每个代表氢原子、取代或未取代的低碳基等);Q代表取代或未取代的苯基等;T代表取代或未取代的低碳基、取代或未取代的芳香基等]。
  • Hsp90 FAMILY PROTEIN INHIBITORS
    申请人:Nara Shinji
    公开号:US20090247522A1
    公开(公告)日:2009-10-01
    The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.
    本发明提供了Hsp90家族蛋白抑制剂,其包含作为活性成分的苯甲酰化合物,其通式表示为(I):(其中n表示0到10的整数;R1表示取代或未取代的低烷氧基,取代或未取代的低烷氧羰基,CONR7R8或类似物;R2表示取代或未取代的芳基,取代或未取代的芳香杂环基或类似物;R3和R5,可以相同也可以不同,分别表示氢原子,取代或未取代的低烷基,取代或未取代的低烯基或类似物;R4和R6,可以相同也可以不同,分别表示氢原子,卤素,取代或未取代的低烷基,取代或未取代的芳基或类似物)或其前药,或其药学上可接受的盐。
  • Hsp90 family protein inhibitors
    申请人:Nara Shinji
    公开号:US20070032532A1
    公开(公告)日:2007-02-08
    The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.
    本发明提供了Hsp90家族蛋白抑制剂,其作为活性成分包括由通式(I)表示的苯甲酰化合物: (其中,n代表0至10的整数;R1代表取代或未取代的较低烷氧基、取代或未取代的较低烷氧羰基、CONR7R8等;R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基等;R3和R5,可以相同也可以不同,每个代表氢原子、取代或未取代的较低烷基、取代或未取代的较低烯基等;R4和R6,可以相同也可以不同,每个代表氢原子、卤素、取代或未取代的较低烷基、取代或未取代的芳基等)或其前药,或所述苯甲酰化合物或其前药的药学上可接受的盐。
查看更多